



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 


PRODUCT INFORMATION



RA-9

Item No. 40838

CAS Registry No.: 919091-63-7
Formal Name: 3E,5E-bis[(4-nitrophenyl)methylene]-4-piperidinone
MF: C₁₉H₁₅N₃O₅
FW: 365.3
Purity: ≥98%
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

RA-9 is supplied as a solid. A stock solution may be made by dissolving the RA-9 in the solvent of choice, which should be purged with an inert gas. RA-9 is sparingly soluble (1-10 mg/ml) in DMSO.

Description

RA-9 is an inhibitor of deubiquitinating enzymes.¹ It inhibits ubiquitin C-terminal hydrolase L1 (UCH-L1), UCH-L3, and ubiquitin-specific protease 8 (USP8) in a cell-free assay when used at a concentration of 10 μM, as well as USP5 in a reporter assay at the same concentration. RA-9 (10 μM) also inhibits the 26S proteasome, but not the 20S proteasome, in a reporter assay using HeLa cervical cancer cells. It increases the levels of polyubiquitinated proteins in HeLa and TOV-21G ovarian cancer cells when used at a concentration of 5 μM. RA-9 (10 μM) induces cell cycle arrest at the S and G₂/M phases in HeLa cells. It decreases the viability of nine cancer cell lines with IC₅₀ values ranging from 1.64 to 12.49 μM. *In vivo*, RA-9 (5 mg/kg every other day) increases survival and decreases tumor and ascitic fluid mass in an ES-2 ovarian cancer mouse xenograft model.²

References

1. Issaenko, O.A., and Amerik, A.Y. Chalcone-based small-molecule inhibitors attenuate malignant phenotype via targeting deubiquitinating enzymes. *Cell Cycle* **11(9)**, 1804-1817 (2012).
2. Coughlin, K., Anchoori, R., Iizuka, Y., *et al.* Small-molecule RA-9 inhibits proteasome-associated DUBs and ovarian cancer *in vitro* and *in vivo* via exacerbating unfolded protein responses. *Clin. Cancer Res.* **20(12)**, 3174-3186 (2014).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 05/22/2024

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM